What is electroCore?
electroCore, Inc. operates at the intersection of advanced medical technology and neurology, specializing in non-invasive vagus nerve stimulation (nVNS). The company's proprietary platform is engineered to address a spectrum of debilitating conditions, including cluster headaches, migraines, and various hemicrania disorders in both adult and adolescent populations. By providing a non-pharmacological alternative for patient care, electroCore is effectively disrupting traditional treatment paradigms. The firm's market position is bolstered by its commitment to clinical efficacy and its ability to navigate the rigorous regulatory landscapes required for commercial-stage bioelectronic health solutions.
How much funding has electroCore raised?
electroCore has raised a total of $227.4M across 7 funding rounds:
Series A
$50M
Debt
$1.5M
Series B
$70M
Stock Offering
$78M
Share Placement
$25M
Debt
$1M
Private Equity
$1.9M
Series A (2014): $50M with participation from Core Ventures Group, Easton Capital, and Merck Global Health Innovation Fund
Debt (2016): $1.5M, investors not publicly disclosed
Series B (2017): $70M supported by Core Ventures Group, Merck Global Health Innovation Fund, American Investment Holdings LLC, Gakasa, and The Vinik Family Foundation
Stock Issuance/Offering (2018): $78M, investors not publicly disclosed
Share Placement (2020): $25M backed by Lincoln Park Capital Fund , LLC
Debt (2020): $1M with participation from PPP
Private Equity (2025): $1.9M, investors not publicly disclosed
Key Investors in electroCore
Core Ventures Group
Core Ventures Group is a venture capital firm that supports world-class entrepreneurs in building valuable businesses, focusing on seed-stage companies with proven business models and advanced technologies.
Easton Capital
Easton Capital Investment Group manages institutional funds and specializes in strategic investments ranging from $2 million to $7.5 million, often participating in larger follow-on rounds.
Merck Global Health Innovation Fund
The Merck Global Health Innovation Fund is the strategic investment arm of Merck & Co., Inc., a global healthcare leader focused on delivering innovative prescription medicines and biologic therapies.
What's next for electroCore?
With the successful closure of this major strategic investment, electroCore is well-positioned to accelerate its clinical development programs and expand the reach of its nVNS therapy. The company's strategic roadmap likely involves scaling its commercial infrastructure to meet the growing demand for non-invasive neurological interventions. Furthermore, the infusion of capital will support ongoing research into additional indications, potentially broadening the therapeutic utility of its platform. As the company transitions into its next phase of maturity, the focus will remain on achieving sustainable market penetration and enhancing patient outcomes through continued innovation in bioelectronic medicine.
See full electroCore company page
